A cohort study to monitor the safety and use of extended-release quetiapine (Seroquel XL) compared to the Immediate Release formulation in the mnetal health trust setting.

Trial Profile

A cohort study to monitor the safety and use of extended-release quetiapine (Seroquel XL) compared to the Immediate Release formulation in the mnetal health trust setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders; Schizophrenia
  • Focus Adverse reactions
  • Acronyms OASIS
  • Most Recent Events

    • 23 Aug 2015 Results presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
    • 22 May 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
    • 31 Mar 2013 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top